Peltomaa R, Paimela L, Helve T, Leirisalo-Repo M
Department of Rheumatology, Kivelä Hospital, Helsinki, Finland.
Scand J Rheumatol. 1995;24(6):330-5. doi: 10.3109/03009749509095176.
We compared the effects of intramuscular gold and sulphasalazine on early, active rheumatoid arthritis in 128 consecutive patients. Intramuscular gold was started in the first 70 consecutive patients and sulphasalazine in the subsequent 58 patients. The patient groups were comparable with regard to clinical characteristics. In both groups clinical and laboratory parameters improved, but there was no significant difference between the two groups. The clinical improvement was most pronounced during the first three months. However, despite the clinical improvement a clear progression in radiological changes was observed in both groups, 40% of the patients taking gold and 48% of patients taking sulphasalazine discontinued the treatment because of adverse drug reactions or inefficacy during the one year follow-up. Adverse drug reactions were the main reason in both groups. These findings suggest that intramuscular gold and sulphasalazine seem to have an equal, positive effect on symptoms and clinical variables, but that radiological progression does occur in most patients none the less.
我们比较了肌肉注射金制剂和柳氮磺胺吡啶对128例连续性早期活动性类风湿关节炎患者的疗效。前70例连续性患者开始使用肌肉注射金制剂，随后的58例患者使用柳氮磺胺吡啶。两组患者在临床特征方面具有可比性。两组患者的临床和实验室参数均有改善，但两组之间无显著差异。临床改善在最初三个月最为明显。然而，尽管有临床改善，但在两组中均观察到放射学改变有明显进展，在一年的随访期间，40%使用金制剂的患者和48%使用柳氮磺胺吡啶的患者因药物不良反应或疗效不佳而停止治疗。药物不良反应是两组患者停药的主要原因。这些发现表明，肌肉注射金制剂和柳氮磺胺吡啶似乎对症状和临床变量有同等的积极作用，但大多数患者仍会出现放射学进展。
